Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.

There is minimal evidence of the benefits of CAR T-cell therapy in individuals with central nervous system-directed autoimmunity. Nevertheless, multicenter controlled clinical trials with a manageable safety profile appear feasible and are warranted due to very promising case experiences.